Haleon plc

Haleon's five OTC categories generate habitual repeat purchases with no formal contracts or subscriptions. Respiratory health and VMS introduce seasonal and discretionary sensitivity, visible in Q4 FY2025 when organic revenue declined 1.0% on a weak cold-and-flu season, while oral care and pain relief are more stable, need-driven categories.

Revenue spans five segments, with oral health as the largest at approximately 31% of FY2024 revenue and pain relief at approximately 24%, and no single segment dominating beyond one third. The end-consumer base is fragmented across millions of pharmacy and retail purchasers globally, with no individual customer representing material concentration.

FY2024 revenue was split across North America (36%), EMEA and LatAm (41%), and APAC (23%), with no single region above 41% and meaningful commercial presence in more than 100 countries. This three-region balance reduces sensitivity to any one regulatory or macroeconomic environment.

Haleon's branded OTC model carries gross margins of approximately 62% in FY2023-FY2024, but operating leverage is constrained by the ongoing advertising and promotion investment required to defend brand positions against private label. Adjusted operating profit margin stood at 24.5% in FY2025, supported by supply chain productivity programs, though the model is not asset-light in the way payment network or software businesses are.

Oral care and pain relief products are non-discretionary, need-driven purchases with strong repeat-purchase dynamics, supporting above-average revenue quality for a branded consumer goods company. Revenue is transactional rather than contractual, and VMS and skin health segments carry some discretionary risk in value-seeking consumer environments.